Abstract��Alzheimer��s disease (AD) is a progressive multifactorial neurodegenerative disorder in elder people. Currently, the pathogenesis of AD is unclear, and it is presently incurable. In view of the complex network pathological features of AD, a single small molecule compound that can act simultaneously with multiple targets, called multi-target directed ligands (MTDLs), is considered to be an effective therapeutic strategy at present. Here, we review highlights recent MTDLs approach based cholinesterase inhibitors, antioxidant, metal chelator and neuroprotectant in the novel drug candidate prototypes for the treatment of AD.
������, ������, ɣ־��. ���������ֺͶ�������Ķ����ҩ����Ƽ��俹�����ĺ�Ĭ�������о���չ[J]. �й�ҩѧ��־, 2019, 54(5): 352-359.
WANG Ke-ren, LIU Wen-min, SANG Zhi-pei. Progress of Multi-Target Directed Drugs Based on Tacrine and Donepezil in Alzheimer��s Disease. Chinese Pharmaceutical Journal, 2019, 54(5): 352-359.
PRINCE M, WIMO A, GUERCHET M, et al. World Alzheimer Report 2015 The Global Impact of Dementia . Alzheimer's Disease International, 2015.
[2]
ASHFORD J W. Treatment of Alzheimer's disease: the legacy of the cholinergic hypothesis, neuroplasticity, and future directions. J Alzheimers Dis, 2015, 47(1): 149-156.
[3]
MOHAMED T, SHAKERI A, RAO P P, et al. Amyloid cascade in Alzheimer's disease: recent advances in medicinal chemistry. Eur J Med Chem, 2016, 113: 258-272.
[4]
KORABECNY J, SPILOVSKA K, MEZEIOVA E, et al. Systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease. Curr Med Chem, 2018, doi: 10.2174/0929867325666180517094023.
[5]
MILELLI A, DE SIMONE A, TICCHI N, et al. Tacrine-based multifunctional agents in Alzheimer's disease: an old story in continuous development. Curr Med Chem, 2017, 24(32): 3522-3546.
[6]
KHOURY R, RAJAMANICKAM J, GROSSBERG G T, et al. An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. Ther Adv Drug Saf,2018, 9(3): 171-178.
[7]
MONEIM A E. Oxidant/antioxidant imbalance and the risk of Alzheimer's disease. Curr Alzheimer Res, 2015, 12(4): 335-349.
[8]
ADLARD P A, BUSH A I. Metals and Alzheimer's disease: how far have we come in the clinic . J Alzheimers Dis, 2018, 62(3): 1369-1379.
[9]
SELLES M C, OLIVEIRA M M, FERREIRA S T. Brain inflammation connects cognitive and non-cognitive symptoms in Alzheimer's disease. J Alzheimers Dis, 2018, doi: 10.3233/JAD-179925.
[10]
LIU K, LIN H H, PI R, et al. Research and development of anti-Alzheimer's disease drugs: an update from the perspective of technology flows. Expert Opin Ther Pat, 2018, 28(4): 341-350.
[11]
DE FREITAS SILVA M, DIAS K S T, GONTIJO V S, et al. Multi-target directed drugs as a modern approach for drug design towards Alzheimer's disease: an update. Curr Med Chem, 2018, doi: 10.2174/0929867325666180111101843.
[12]
CHEN L, FANG L, FANG X, et al. Progress of multi-target directed drugs based on AChE inhibitors in Alzheimer's disease. Chin Pharm J (�й�ҩѧ��־), 2010, 45(21): 1606-1611.
[13]
ANAND P, SINGH B. A review on cholinesterase inhibitors for Alzheimer's disease. Arch Pharm Res, 2013, 36: 375-399.
[14]
XIE S S, WANG X, JIANG N, et al. Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. Eur J Med Chem, 2015, 95:153-165.
[15]
WANG X Q, XIA C L, CHEN S B, et al. Design, synthesis, and biological evaluation of 2-arylethenylquinoline derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem, 2015, 89:349-361.
[16]
FU Y, MU Y, LEI H, et al. Design, synthesis and evaluation of novel tacrine-ferulic acid hybrids as multifunctional drug candicates against Alzheimer's disease. Molecules, 2016, 21(10).pii: E1338.
[17]
BENCHEKROUN M, ROMERO A, EGEA J, et al. The antioxidant additive approach for Alzheimer's disease therapy: new ferulic (lipoic) acid plus melatonin modified tacrines as cholinesterases inhibitors, direct antioxidants, and nuclear factor (erythroid-derived 2)-like 2 activators. J Med Chem, 2016, 59(21):9967-9973.
[18]
CHIOUA M, PEREA-PENA J, GARCIA-FONT N, et al. Pyranopyrazolotacrines as nonneurotoxia A��-anti-aggregating and neuroprotective agents for Alzheimer's disease. Future Med Chem, 2015, 7(7):845-855.
[19]
OSET-GASQUE M J, MARCO-CONTELLES J. New tacrines as anti-Alzheimer's disease agents. The (benzo)chromeno-pyranotacrines. Curr Top Med Chem, 2017, 17(31): 3349-3360.
[20]
DERABLI C, BOUALIA I, ABDELWAHAB A B, et al. A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel tacrine-pyranopyrazole derivatives. Bioorg Med Chem Lett, 2018, pii: S0960-894X(18)30476-1.
[21]
CZARNECKA K, CHUFAROVA N, HALCZUK K, et al. Tetrahydroacridine derivatives with dichloronicotinic acid moiety as attractive multipotent agents for Alzheimer's disease treatment. Eur J Med Chem, 2018, 145:760-769.
[22]
CEN J, GUO H, HONG C, et al. Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity. Eur J Med Chem, 2018, 144:128-136.
[23]
SPILOVSKA K, KORABECNY J, SEPSOVA V, et al. Novel tacrine-scutellarin hybrids as multipotent anti-Alzheimer's agents: design, synthesis and biological evaluation. Molecules, 2017, 22(6),pii: E1006.
[24]
CHUFAROVA N, CZARNECKA K, SKIBINSKI R, et al. New tacrine-acridine hybrids as promising multifunctional drugs for potential treatment of Alzheimer's disease. Arch Pharm (Weinheim), 2018, 351(7):e1800050.
[25]
CHIOUA M, BUZZI E, MORALEDA I, et al. Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease. Eur J Med Chem, 2018, 155: 839-846.
[26]
WU M T, ESTEBAN G, BROGI S, et al. Donepezil-like multifunctional agents: design, synthesis, molecular modeling and biological evaluation. Eur J Med Chem, 2016, 121: 864-879.
[27]
GUZIOR N, BAJDA M, RAKOCZY J, et al. Isoindoline-1,3-dione derivatives targeting cholinesterases: design, synthesis and biological evaluation of potential anti-Alzheimer's agents. Bioorg Med Chem, 2015, 23 (7):1629-1637.
[28]
WIECKOWSKA A, WIECKOWSKI K, BAJDA M, et al. Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with ��-amyloid anti-aggregation properties and beneficial effects on memory in vivo. Bioorg Med Chem, 2015, 23 (10): 2445-2457.
[29]
QIANG X, SANG Z, YUAN W, et al. Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease . Eur J Med Chem, 2014, 76 (1):314-331.
[30]
DIAS K S, DE PAULA C T, DOS SANTOS T, et al. Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multi-target drugs for the treatment of Alzheimer's disease. Eur J Med Chem, 2017, 130: 440-457.
[31]
SANG Z, PAN W, WANG K, et al. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem, 2017, 130: 379-392.
[32]
SANG Z, QIANG X, LI Y, et al. Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem, 2015, 94: 348-366.
[33]
SANG Z, QIANG X, LI Y, et al. Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem, 2017, 135: 307-323.
[34]
DIAS VIEGAS F P, DE FREITAS SILVA M, DIVINO DA ROCHA M, et al. Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: discovery of novel multi-target anti-alzheimer prototype drug candidates. Eur J Med Chem, 2018, 147: 48-65.
[35]
HUANG W, WANG Y, LI J, et al. Design, synthesis and evaluation of genipin derivatives for the treatment of Alzheimer's disease. Chem Biol Drug Des, 2018, doi: 10.1111/cbdd.13194.
[36]
CHIERRITO T P C, PEDERSOLI-MANTOANI S, ROCA C, et al. Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: potent butyrylcholinesterase inhibitors. Eur J Med Chem, 2018, 145: 431-444.
[37]
CAI P, FANG S Q, YANG X L, et al. Rational design and multibiological profiling of novel donepezil-trolox hybrids against Alzheimer's disease, with cholinergic, antioxidant, neuroprotective, and cognition enhancing properties. ACS Chem Neurosci, 2017, 8(11): 2496-2511.
[38]
VALENCIA M E, HERRERA AROZAMENA C, DE ANDRES L, et al. Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. Eur J Med Chem, 2018, 156: 534-553.
2019, Vol. 54 
